A Phase I, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy(SMD)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MA09 retinal pigment epithelial cell replacement therapy-Astellas Pharma (Primary)
Indications Stargardt disease
Focus Adverse reactions
Sponsors CHA Bio & Diostech

Most Recent Events

06 Feb 2024 Status changed from active, no longer recruiting to completed.
24 Jun 2015 According to Ocata Therapeutics media release, pooled data from this and other four trials (see profiles 700243697, 700243711, 700255314, 700243638) has been presented as a Late Breaking Abstract at the International Society for Stem Cell Research (ISSCR) 13th Annual Meeting.
28 Apr 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight